SALVOVAR is project funded by the European Commission under the Horizon program. It is a European multi-disciplinary clinical project meant to improve the management of patients with poor prognostic ovarian cancer after neoadjuvant chemotherapy.
It is a pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose and dosing schedule with the SALVage (SALVOVAR) weekly dose-dense regimen in patients with poor prognostic OVARian (SALVOVAR) cancers based on the poor tumor primary chemosensitivity and incomplete debulking surgery.
Company Details
- Employees
- 1
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- http://www.salvovar.eu
- Keywords
- IMAGYN.
Salvovar Questions
Salvovar's website is http://www.salvovar.eu
Salvovar's LinkedIn profile is https://www.linkedin.com/company/salvovar
Salvovar has
1 employees.
View email and phone details for 1
employees at Salvovar.
Salvovar's industry is
Hospitals and Health Care
Salvovar's top competitors are
Mediya,
Aem2 - Association Des Etudiants En Médecine De Marseille,
Université Mohamed Vi Des Sciences Et De La Santé,
International Cancer Foundation (Icf),
Pediatría Al Día,
Haute Autorité De Santé,
Care1 Project,
Institut Du Sein Marseille-Provence - Ismp,
Imagyn,
Arcagy-Gineco.
Salvovar's categories are Hospitals and Health Care
